FDA Approves Updated Prescribing Info for Amgen's Melanoma Treatment Imlygic

Amgen announced that the FDA has approved an update to the Prescribing Information for Imlygic (talimogene laherparepvec), a treatment for melanoma. This update is not related to any new safety information but rather a clarification of existing data.

The company did not provide further details on the changes made to the Prescribing Information, which will now reflect the most current and accurate information regarding the use of Imlygic in treating melanoma patients.